Introducing the Galleri multi-cancer early detection test

Galleri is a blood test that can detect 50+ cancer types and can be taken annually.1,2

Request your Galleri test
Already have an account? Log in

The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

illustrated video poster of the Galleri test sitting on a table in an examination room with an anatomy poster on the wall behind it

The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Who is eligible?

The Galleri Test valued at $949 is available at no cost to Active Carpenters, Early Retirees, and their eligible spouse aged 50 and older or aged 40-49 with elevated risk factors. Participants covered under the Carpenters’ Medicare Plan are not eligible for the Galleri test.

Active Carpenters & Early Retirees

  • Aged 50 years old or older 
  • Aged 40-49 with elevated risk factors
  • Not covered under the Carpenters’ Medicare Plan
  • 40-49 and at least one of the following risk factors:
    • Personal history of cancer (Galleri was studied in individuals at least three years post-cancer treatment)*
    • Current smoker or history of smoking
    • Obesity
    • Diabetes
    • Family history of cancer (first degree relative)
    • Hereditary genetic predisposition
    • Occupational exposures (e.g. burn pits, asbestos)
    • Environmental exposures (e.g. alcohol consumption, sun exposure)
    • Autoimmune chronic inflammatory conditions (e.g. IBD, asthma)
    • Non-autoimmune chronic inflammatory conditions (e.g. cirrhosis, chronic hepatitis B/C)
    • Immunodeficiencies (e.g. primary or viral, such as HIV or HPV)
    • Solid organ transplantation

*Excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis.

Please note that the Galleri test is not available for people who are currently pregnant or undergoing cancer treatment.

Walt Testimonial

Spouses

  • Aged 50 years old or older 
  • Aged 40-49 with elevated risk factors
  • Not covered under the Carpenters’ Medicare Plan
  • 40-49 and at least one of the following risk factors:
    • Personal history of cancer (Galleri was studied in individuals at least three years post-cancer treatment)*
    • Current smoker or history of smoking
    • Obesity
    • Diabetes
    • Family history of cancer (first degree relative)
    • Hereditary genetic predisposition
    • Occupational exposures (e.g. burn pits, asbestos)
    • Environmental exposures (e.g. alcohol consumption, sun exposure)
    • Autoimmune chronic inflammatory conditions (e.g. IBD, asthma)
    • Non-autoimmune chronic inflammatory conditions (e.g. cirrhosis, chronic hepatitis B/C)
    • Immunodeficiencies (e.g. primary or viral, such as HIV or HPV)
    • Solid organ transplantation

*Excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis.

Please note that the Galleri test is not available for people who are currently pregnant or undergoing cancer treatment.

Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them
Already have an account? Log in

Limited data exists regarding the performance of the Galleri test in individuals <50 years of age.2,3,4

Galleri for EAS Carpenters Benefit Funds Program

The Galleri Test valued at $949 is available at no cost to Active Carpenters, Early Retirees, and their eligible spouse aged 50 and older or aged 40-49 with elevated risk factors. Participants covered under the Carpenters’ Medicare Plan are not eligible for the Galleri test.

To request a test, you will need an Access ID. Your Access ID is the first initial of your first name, your last name and your date of birth.

Example Patient's Access ID:
Patient First Name: John
Patient Last Name: Smith
Patient Date of Birth: 01/01/1950
Patient's Access ID: jsmith01011950

Note: If your last name has a hyphen, do not include the hyphen in your Access ID.

Eligible individuals can request the test once every 12 months from the time of blood draw.

Screen for more in 4 simple steps

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Request the test

It will take about 10 minutes to complete an online health questionnaire about your medical history. The Galleri test, by GRAIL, is available by prescription only. By requesting the test and completing the questionnaire, you’re requesting a prescription from Recuro Health, an independent telemedicine provider.

illustrated graphic of the Galleri test box sitting on a table in front of a window

Receive a collection kit

If the Recuro Health telemedicine provider confirms your eligibility and prescribes the Galleri test, you will receive a notification via email and a collection kit in the mail. Visit Galleri.com/schedule to book your blood draw appointment at a GRAIL blood draw partner.

illustrated graphic of a white, gray haired female patient having her blood drawn

Provide your sample

Bring your test kit and Test Requisition Form (TRF) with you to the appointment. A trained technician will draw your blood sample and ship the kit to the GRAIL lab.

Illustrated graphic of a black man sitting in a blue armchair and reviewing test results on a tablet

Receive your results

Recuro Health will contact you when your result is ready — about 2-3 weeks after your blood is received at the GRAIL lab.

Already have an account? Log in

What does the Galleri test result mean?


The Galleri test detected DNA fragments associated with cancer in your blood sample. About 1 out of every 100 test has a Cancer Signal Detected result.5

This result will also include a prediction of the issue type or organ associated with the cancer signal, called a Cancer SIgnal Origin (CSO). This provides direction to your doctor on the cancer’s origin and can help guide the next steps for diagnosis.2,8

In a clinical study, around 6 out of 10 people with a Cancer Signal Detected result were diagnosed with cancer after diagnostic testing.13* 

Cancer signal detected thumb
NEXT STEPS

A Cancer Signal Detected test result is not a cancer diagnosis and requires follow-up diagnostic testing. Such testing may include lab work or imagining ordered by your healthcare provider to confirm cancer. 

*Based on the first ~25,000 participants with 1 year of follow-up. 

The Galleri test did not detect DNA fragments associated with cancer in your blood sample. 

Nearly 99% of people who use the Galleri test will screen negative.5 

This result does not completely rule out the possibility of cancer. While the Galleri test is a powerful tool, it cannot detect a signal for all cancers and not all cancers can be detected in the blood. Some cancers shed little or no DNA into the bloodstream, making them unlikely to be detected through a blood test (e.g., brain, skin, and early-stage breast and prostate cancers).14 False positive and false negative results do occur. This result does not predict whether you will develop cancer in the future. 

Cancer signal not detected thumb
NEXT STEPS

Continue with any routine cancer screenings your healthcare provider recommends. Do not ignore cancer signs or symptoms if they occur, as this could lead to delayed diagnosis. 

Cancer can be unpredictable. The Galleri test can be taken as a simple blood test. Adding the Galleri test to an annual routine can improve your chance of finding cancer early.12

CancerNavigator

EAS Carpenters Benefit Funds partners with CancerNavigator to ensure that members with a positive signal on their Galleri test have the support they need for diagnostic testing and next steps. CancerNavigator's dedicated Oncology Nurse Navigators can answer questions members may have related to a suspected or confirmed diagnosis, and can provide education and guidance at every step. For any questions about cancer support services please call EAS Carpenters Benefit Funds' dedicated CancerNavigator support line at (267)-579−2717.

Cancer screening with Galleri can make a difference

Galleri looks for many deadly cancers before symptoms appear from a single blood draw and identifies a unique “fingerprint” of 50+ cancers, including many without a recommended screening available today.
  • Jackie

    Patient testimonial: Jackie

    Cancer Signal Detected
    Read Jackie's full story

  • Cindy testimonial preview

    Patient testimonial: Cindy

    Cancer Signal Detected

  • Jonathan Testimonial Lyphoma

    Patient testimonial: Jonathan

    Cancer Signal Detected

  • Rich testimonials

    Patient testimonial: Rich

    Cancer Signal Detected

  • Mary patient vid

    Patient testimonial: Mary

    Cancer Signal Detected

  • Roger testimonial

    Patient testimonial: Roger

    Cancer Signal Detected

  • Valerie

    Patient testimonial: Valerie

    Cancer Signal Detected

  • Patient story video still closeup of Tami

    Patient testimonial: Tami

    No Cancer Signal Detected

  • patient story video still of Keith and his wife on a walk

    Patient testimonial: Keith

    No Cancer Signal Detected

  • Jennifer Testimonial poster

    Patient testimonial: Jennifer

    No Cancer Signal Detected
    Read Jennifer's full story

  • Rich S Taci

    Patient testimonial: Rich & Staci

    Cancer Signal Detected
    Read Rich & Staci's full story

  • Oncologist perspective

    Oncologist Perspectives

1 / 12

Frequently Asked Questions for Eastern Atlantic States Carpenters Benefit Funds

Additional Frequently Asked Questions about the Galleri test

The Galleri Test valued at $949 is available at no cost to Active Carpenters, Early Retirees, and their eligible spouse aged 50 and older or aged 40-49 with elevated risk factors. Participants covered under the Carpenters’ Medicare Plan are not eligible for the Galleri test.

To access the Galleri test as a covered benefit, you must request the test through this web page. 

When you request the test, an independent telemedicine healthcare provider will review your request and order it if appropriate. The test is available by prescription only.

The cost of the Galleri test, blood draw, and laboratory fees are all covered under this benefit.

An at-home or in-lab blood draw is included in the price of the test if scheduled with one of our partner labs. Find a time and location convenient for you.

When requesting the Galleri test you will need to provide an “Access ID” to confirm eligibility for the benefit. Your Access ID is the first initial of your first name, your last name and your date of birth.

Example Patient's Access ID:

Patient First Name: John
Patient Last Name: Smith
Patient Date of Birth: 01/01/1950
Patient's Access ID: jsmith01011950

Note: If your last name has a hyphen, do not include the hyphen in your Access ID.

Under the EAS Carpenters Benefit Funds program, eligible individuals are able to complete the Galleri test every 12 months.

To access the Galleri test as a covered benefit, you must request the test through this web page. An independent telemedicine provider will review your request and order the test, if appropriate.

The Galleri test is provided at no cost to eligible individuals only when obtained through this authorized site.

The blood draw associated with the Galleri test must occur on a date you are covered under this benefit.

Individuals are responsible for the full cost of the test when obtained via any other means, such as a personal physician, or when the blood draw date of service occurs after the benefit coverage has ended.

Get support

For questions about the Galleri test, please contact GRAIL Customer Service:

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes

  1. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screening [cited 2025 Mar 18]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results
  2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
  3. Matrana M, Shukla V, Kingsbury D, et al. Real‑world data and clinical experience from over 100,000 multi‑cancer early detection tests [poster]. American Association for Cancer Research (AACR) Annual Meeting; 2025 Apr 25-30; Chicago. https://assets.grail.com/wp-content/uploads/2025/04/7202.Matrana.AACR-2025-RWE-100K_Poster_Final.pdf
  4. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251-60. doi: 10.1016/S0140-6736(23)01700-2
  5. GRAIL, Inc. Enhanced Cancer Signal Origin prediction. [Data on file: VV-TMF-59592]
  6. Nabavizadeh N, et al. Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: initial results from the registrational PATHFINDER2 study [proffered presentation]. European Society for Medical Oncology (ESMO) Annual meeting: 2025 Oct 17-21; Berlin.
  7. Bredno J, Venn O, Chen X, et al. Circulating tumor DNA allele fraction: a candidate biological signal for multi-cancer early detection tests to assess the clinical significance of cancers. Am J Pathol. 2022; 192(10):1368-78. doi:10.1016/j.ajpath.2022.07.007
  8. Sasieni P, Clarke CA, Hubbell E. Impact of MCED screening interval on reduction in late-stage cancer diagnosis and mortality. European Society for Medical Oncology (ESMO) Virtual Congress [poster]; 2021 Sep 16-21.